A股異動︱美達股份升停 定增募資不超5.94億元獲通過
美達股份(000782.SZ)升停,報5.97元,創2020年9月以來新高,總市值31.53億元。美達股份昨日公吿,向特定對象發行股票申請獲得深交所上市審核中心審核通過。公司先前公吿,擬向福建力恒投資有限公司發行股票數量不超過1.58億股,發行價格為3.75元/股,募集資金總額為不超5.94億元,扣除發行費用後的淨額將全部用於償還銀行貸款及補充公司流動資金。本次發行完成後,李堅之通過昌盛日電享有上市公司17.28%的表決權,認購方力恒投資享有上市公司24.59%的表決權。本次發行完成後,力恒投資成為上市公司控股股東,陳建龍成為上市公司實際控制人。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.